End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
25 CAD | +1.46% | +0.36% | +10.28% |
06-28 | Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU | MT |
06-28 | AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company is in debt and has limited leeway for investment
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 29.91 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.28% | 303B | - | ||
+55.32% | 815B | C+ | ||
-6.75% | 352B | C+ | ||
+13.56% | 314B | B- | ||
+16.57% | 242B | B+ | ||
+2.04% | 224B | A+ | ||
+13.31% | 218B | B- | ||
+8.48% | 168B | C+ | ||
-2.81% | 159B | C+ | ||
+0.20% | 120B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ABBV Stock
- ABBV Stock
- Ratings AbbVie Inc.